Published in Mult Scler on December 07, 2009
Intervention for Young Adults With Multiple Sclerosis (ESPRIMO) | NCT04431323
Understanding Mental Fatigue After Stroke (MenFAS) | NCT04866420
Self-report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: a systematic review of measurement properties. Qual Life Res (2011) 1.11
Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis. PLoS One (2014) 1.10
Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS One (2013) 0.98
Inhibition of IL-1beta improves fatigue in type 2 diabetes. Diabetes Care (2011) 0.95
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord (2011) 0.94
Mindfulness-based interventions in multiple sclerosis: beneficial effects of Tai Chi on balance, coordination, fatigue and depression. BMC Neurol (2014) 0.91
Advanced MRI unravels the nature of tissue alterations in early multiple sclerosis. Ann Clin Transl Neurol (2014) 0.91
Objective assessment of motor fatigue in multiple sclerosis: the Fatigue index Kliniken Schmieder (FKS). J Neurol (2014) 0.90
Third ventricular enlargement in early stages of multiple sclerosis is a predictor of motor and neuropsychological deficits: a cross-sectional study. BMJ Open (2013) 0.84
Objective assessment of motor fatigue in Multiple Sclerosis using kinematic gait analysis: a pilot study. J Neuroeng Rehabil (2011) 0.84
Management of fatigue in persons with multiple sclerosis. Front Neurol (2014) 0.83
Structural correlates for fatigue in early relapsing remitting multiple sclerosis. Eur Radiol (2015) 0.80
Multicontrast MRI Quantification of Focal Inflammation and Degeneration in Multiple Sclerosis. Biomed Res Int (2015) 0.80
Faith as a resource in patients with multiple sclerosis is associated with a positive interpretation of illness and experience of gratitude/awe. Evid Based Complement Alternat Med (2013) 0.80
Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis. Front Neurol (2015) 0.79
The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. EPMA J (2016) 0.79
Selecting Rehabilitation Outcome Measures for People with Multiple Sclerosis. Int J MS Care (2015) 0.79
Case-Based fMRI Analysis after Cognitive Rehabilitation in MS: A Novel Approach. Front Neurol (2015) 0.79
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology (2016) 0.78
The Impact of MS-Related Cognitive Fatigue on Future Brain Parenchymal Loss and Relapse: A 17-Month Follow-up Study. Front Neurol (2016) 0.77
Difference in Motor Fatigue between Patients with Stroke and Patients with Multiple Sclerosis: A Pilot Study. Front Neurol (2014) 0.77
Endurance training in MS: short-term immune responses and their relation to cardiorespiratory fitness, health-related quality of life, and fatigue. J Neurol (2013) 0.76
Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol (2014) 0.76
Oxygen cost of walking in persons with multiple sclerosis: disability matters, but why? Mult Scler Int (2014) 0.76
MP2RAGE provides new clinically-compatible correlates of mild cognitive deficits in relapsing-remitting multiple sclerosis. J Neurol (2014) 0.76
Fatigue in Multiple Sclerosis Compared to Stroke. Front Neurol (2015) 0.75
Development and Feasibility of an Evidence-Based Patient Education Program for Managing Fatigue in Multiple Sclerosis: The "Fatigue Management in MS" Program (FatiMa). Int J MS Care (2016) 0.75
Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study. BMC Neurol (2016) 0.75
Impact of a 5-day expedition to machu picchu on persons with multiple sclerosis. Mult Scler Int (2014) 0.75
Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness. Front Neurol (2015) 0.75
Counteracting Fatigue in Multiple Sclerosis with Right Parietal Anodal Transcranial Direct Current Stimulation. Front Neurol (2016) 0.75
Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod. BMC Neurol (2016) 0.75
Fluctuations of spontaneous EEG topographies predict disease state in relapsing-remitting multiple sclerosis. Neuroimage Clin (2016) 0.75
Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol (2017) 0.75
Subjective Cognitive Fatigue and Autonomic Abnormalities in Multiple Sclerosis Patients. Front Neurol (2017) 0.75
Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study. J Neurol (2017) 0.75
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry (2004) 2.91
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology (2010) 2.33
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 2.07
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology (2010) 2.04
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A (1990) 1.93
Self glycolipids as T-cell autoantigens. Eur J Immunol (1999) 1.93
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology (2011) 1.83
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology (2011) 1.75
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73
The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity (2000) 1.72
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler (2009) 1.65
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology (1990) 1.61
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev (2001) 1.59
Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 1.57
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology (1997) 1.55
Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology (2003) 1.54
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45
[New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?]. Dtsch Med Wochenschr (2005) 1.39
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29
Impaired episodic memory retrieval in a case of probable psychogenic amnesia. Psychiatry Res (1997) 1.29
Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler (2003) 1.28
Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol (2009) 1.27
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology (2011) 1.25
MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler (2006) 1.25
Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol (2007) 1.24
Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology (1995) 1.19
Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand (2009) 1.17
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain (1998) 1.15
Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol (2002) 1.10
A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility. Genes Immun (2011) 1.08
Predictors of relapse rate in MS clinical trials. Neurology (2005) 1.06
MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol (2009) 1.05
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler (2013) 1.05
Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control. Mult Scler (2007) 1.05
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology (2012) 1.05
Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. Exp Brain Res (2008) 1.04
The amygdala's contribution to memory--a study on two patients with Urbach-Wiethe disease. Neuroreport (1994) 1.04
Anterior pituitary axis hormones and outcome in acute ischaemic stroke. J Intern Med (2011) 1.03
Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol (2000) 1.02
Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology (2005) 1.01
Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology (2001) 1.01
Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology (2006) 1.01
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. Mult Scler (2011) 0.99
Magnetic resonance imaging and early diagnosis of multiple sclerosis. Lancet (1988) 0.99
[Facial myokymia caused by pontine lesions and central fever in multiple sclerosis--case report]. Schweiz Rundsch Med Prax (1991) 0.98
Reproducibility of fMRI in the clinical setting: implications for trial designs. Neuroimage (2008) 0.98
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology (2010) 0.97
The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain (2001) 0.97
Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. J Magn Reson Imaging (2000) 0.97
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler (2013) 0.97
Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology (2011) 0.94
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler (2010) 0.94
MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. Neurology (2003) 0.93
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand (2013) 0.93
BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol (2010) 0.92
Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. Neurology (2001) 0.92
Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology (2011) 0.91
Chess expertise and memory for chess positions in children and adults. J Exp Child Psychol (1993) 0.91
Interferon β-1b and glatiramer acetate effects on permanent black hole evolution. Neurology (2011) 0.91
Visual and motor evoked potentials in the course of multiple sclerosis. Brain (2001) 0.90
Prediction of long-term disability in multiple sclerosis. Mult Scler (2011) 0.90
Short-term adaptation to a simple motor task: a physiological process preserved in multiple sclerosis. Neuroimage (2008) 0.89
Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology (2005) 0.89
Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter. Magn Reson Med (1995) 0.88
Gelatinase B [matrix metalloproteinase (MMP)-9] and collagenases (MMP-8/-13) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children. Neuropathol Appl Neurobiol (2006) 0.88
Combined acute disseminated encephalomyelitis and acute motor axonal neuropathy after vaccination for hepatitis A and infection with Campylobacter jejuni. J Neurol (1999) 0.88
Escalating immunotherapy of multiple sclerosis--new aspects and practical application. J Neurol (2004) 0.88
Balancing the Th1/Th2 concept in multiple sclerosis. Immunol Today (1998) 0.88
Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Mult Scler (2010) 0.87
Evoked potentials for evaluation of multiple sclerosis. Clin Neurophysiol (2001) 0.87
T cell receptor gamma delta repertoire is skewed in cerebrospinal fluid of multiple sclerosis patients: molecular and functional analyses of antigen-reactive gamma delta clones. Eur J Immunol (1995) 0.87
Interferon beta-1b treatment does not induce autoantibodies. Neurology (2005) 0.87
The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology (2003) 0.86
Comparison between the respiratory inductance plethysmography signal derivative and the airflow signal. Adv Exp Med Biol (2001) 0.86
Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler (2004) 0.86
Indication for psychotherapy in offspring of a parent affected by a chronic somatic disease (e.g. multiple sclerosis). Psychopathology (2005) 0.85
MRI study of Baló's concentric sclerosis before and after immunosuppressive therapy. J Neurol (1989) 0.85
Gangliosides and autoimmune neuropathies: classification and clinical aspects of autoimmune neuropathies. J Neurol Neurosurg Psychiatry (1994) 0.85
Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology (2006) 0.85
Neuropsychological dysfunction, depression, physical disability, and coping processes in families with a parent affected by multiple sclerosis. Mult Scler (2008) 0.84
New statistical method for detection and quantification of respiratory sinus arrhythmia. IEEE Trans Biomed Eng (1999) 0.84